- Home
- BCLI vs ADTX Comparison
BCLI vs ADTX Comparison
Compare BCLI & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCLI
- ADTX
- Stock Information
- Founded
- BCLI 2000
- ADTX 2017
- Country
- BCLI United States
- ADTX United States
- Employees
- BCLI N/A
- ADTX N/A
- Industry
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- ADTX Biotechnology: Pharmaceutical Preparations
- Sector
- BCLI Health Care
- ADTX Health Care
- Exchange
- BCLI Nasdaq
- ADTX Nasdaq
- Market Cap
- BCLI 6.4M
- ADTX 5.3M
- IPO Year
- BCLI N/A
- ADTX 2020
- Fundamental
- Price
- BCLI $0.92
- ADTX $2.30
- Analyst Decision
- BCLI Strong Buy
- ADTX
- Analyst Count
- BCLI 1
- ADTX 0
- Target Price
- BCLI $30.00
- ADTX N/A
- AVG Volume (30 Days)
- BCLI 366.6K
- ADTX 595.9K
- Earning Date
- BCLI 05-13-2025
- ADTX 05-19-2025
- Dividend Yield
- BCLI N/A
- ADTX N/A
- EPS Growth
- BCLI N/A
- ADTX N/A
- EPS
- BCLI N/A
- ADTX N/A
- Revenue
- BCLI N/A
- ADTX $133,985.00
- Revenue This Year
- BCLI N/A
- ADTX $15,768.94
- Revenue Next Year
- BCLI N/A
- ADTX N/A
- P/E Ratio
- BCLI N/A
- ADTX N/A
- Revenue Growth
- BCLI N/A
- ADTX N/A
- 52 Week Low
- BCLI $0.72
- ADTX $2.04
- 52 Week High
- BCLI $10.05
- ADTX $27,200.00
- Technical
- Relative Strength Index (RSI)
- BCLI 35.85
- ADTX 30.49
- Support Level
- BCLI $1.12
- ADTX $2.04
- Resistance Level
- BCLI $0.82
- ADTX $2.39
- Average True Range (ATR)
- BCLI 0.12
- ADTX 0.45
- MACD
- BCLI 0.01
- ADTX 0.48
- Stochastic Oscillator
- BCLI 36.36
- ADTX 7.54
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.